IGF1 and acromegaly: In a 36-week, randomized placebo-controlled study in patients with acromegaly controlled on injected SRL therapy, IGF-I was maintained at or below the upper limit of normal in 58.2% of patients treated with oral octreotide and 19.4% who received placebo (28).